文献速递肿瘤 PET/CT

黑色素靶向[18F]-PFPN PET显像可为透明细胞肉瘤诊断提供线索

Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-09-16

这项前瞻性单中心研究纳入3例病理确诊的透明细胞肉瘤患者,在1周内分别行[18F]-FDG PET/CT与[18F]-PFPN PET/MRI。[18F]-PFPN PET共检出56个病灶,两种显像互有漏检;[18F]-FDG的SUVmean高于[18F]-PFPN(P=0.01)。作者认为[18F]-PFPN PET对透明细胞肉瘤诊断可行,两种示踪剂具互补作用,联合使用更可取。

要点

  • [18F]-FDG PET有12个病灶(30.77%)在[18F]-PFPN PET上漏检。
  • [18F]-PFPN PET有20个病灶(42.55%)在[18F]-FDG PET上漏检。
  • 作者认为两种示踪剂显像特征不同且互补,联合使用更可取。

核心结论

  • 作者认为黑色素靶向[18F]-PFPN PET显像用于透明细胞肉瘤诊断是可行的。
  • [18F]-PFPN与[18F]-FDG PET显示不同的显像特征,体现两种示踪剂的互补作用,作者认为联合使用两种显像方法更可取。

研究设计与样本

  • 前瞻性单中心研究,招募病理确诊的透明细胞肉瘤患者。
  • [18F]-FDG PET/CT与[18F]-PFPN PET/MRI在彼此间隔1周内完成。
  • 共招募3例患者并接受PET显像,收集病灶数目及[18F]-FDG与[18F]-PFPN的SUVmax、SUVmean、MTV/MLTV、TLG/TLM。
  • 临床试验注册号NCT05963035。

主要发现

  • [18F]-PFPN PET共检出56个病灶,包括原发肿瘤与远处转移灶。
  • [18F]-FDG显像的39个病灶中有12个(12/39,30.77%)在[18F]-PFPN显像上漏检。
  • [18F]-PFPN显像的47个病灶中有20个(20/47,42.55%)在[18F]-FDG显像上漏检。
  • 全部病灶中[18F]-FDG的SUVmean(4.60 ± 3.24)高于[18F]-PFPN的SUVmean(3.0 ± 2.63),P = 0.01。
  • [18F]-PFPN与[18F]-FDG的SUVmax、SUVmean、MLTV/MTV、TLM/TLG之间均无显著相关性(P > 0.05)。

关键数值与推荐

  • 全部病灶中[18F]-FDG的SUVmean为4.60 ± 3.24,高于[18F]-PFPN的SUVmean 3.0 ± 2.63(P = 0.01)。
  • [18F]-FDG与[18F]-PFPN的SUVmax、SUVmean、MLTV/MTV、TLM/TLG之间无显著相关性(P > 0.05)。

临床怎么用

  • 作者认为联合使用[18F]-PFPN与[18F]-FDG两种显像方法在透明细胞肉瘤患者中更可取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intracytoplasmic melanin pigment is a characteristic of clear cell sarcoma (CCS), which is a particularly deadly type of soft-tissue sarcoma. [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]-PFPN) is a positron emission tomography (PET) probe characterized by high melanin affinity. Therefore, this study aimed to investigate the feasibility of melanin-targeted [18F]-PFPN PET in patients with CCS. METHODS: This prospective single-centre study recruited patients with pathologically confirmed CCS. [18F]-FDG PET/computed tomography and [18F]-PFPN PET/magnetic resonance imaging scans were performed within 1 week of each other. The lesion numbers and [18F]-FDG and [18F]-PFPN PET parameters (maximum standardized uptake value [SUVmax], mean standardized uptake value [SUVmean], metabolic/melanotic tumour volume [MTV/MLTV], and total lesion glycolysis/melanin [TLG/TLM]) were collected. RESULTS: Three patients with CCS were recruited and received PET imaging. A total of 56 lesions were detected on [18F]-PFPN PET, including primary tumour and distant metastases. Identical lesions were not detected on [18F]-PFPN and [18F]-FDG PET. Twelve lesions (12/39, 30.77%) on [18F]-FDG imaging were missed on [18F]-PFPN, and 20 lesions (20/47, 42.55%) on [18F]-PFPN imaging were missed on [18F]-FDG. In quantitative analysis, the [18F]-FDG SUVmean (4.60 ± 3.24) was higher than the [18F]-PFPN SUVmean (3.0 ± 2.63) in all lesions (P = 0.01). No significant correlations were found between the SUVmax, SUVmean, MLTV/MTV, and TLM/TLG values of [18F]-PFPN and [18F]-FDG (P > 0.05). CONCLUSION: Melanin-targeted [18F]-PFPN PET imaging is feasible for the diagnosis of CCS. Different imaging features were displayed on [18F]-PFPN and [18F]-FDG PET imaging, demonstrating the complementary role of the tracers. Combined use of the two imaging modalities would be preferred in patients with CCS. CLINICAL TRIAL REGISTRATION: NCT05963035.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang X, Kang F, Zheng H, et al. Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37714979. doi:10.1007/s00259-023-06439-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。